Gram-positive infections: Pharmacy issues and strategy for quinupristin/dalfopristin

The development of the first streptogramin antibiotic, quinupristin/dalfopr istin represents an attempt to bring new antimicrobial strategies on line t o combat the menacing problem of Gram-positive-resistant bacteria. With int roduction to the medical center formulary, the pharmacy will need to be awa re of several practical issues surrounding the use of quinupristin/dalfopri stin. Cost and unit size will be important issues. Initially, this drug wil l only be available in 500-mg vials which may not always accommodate the su ggested dose of 7.5 mg/kg of actual body weight. In addition, the drug can only be reconstituted with D5W or sterile water, and it can not be mixed wi th normal saline, heparin, or other drugs. Institutions adding this drug to their formularies must address the expected logistical concerns with their medical, nursing, and pharmacy staffs prior to patient usage. (C) 1999 Els evier Science Inc.